A phase 3, intergroup multicentre, randomized, controlled 3 arm parallel group study to determine the efficacy and safety of lenalidomide in combination with dexamethasone (rd) versus melphalan, prednisone and lenalidomide (mpr) versus cyclophosphamide, prednisone and lenalidomide (cpr) in newly diagnosed multiple myeloma elderly subjects
A Randomized Phase III Study to Compare Bortezomib, Melphalan, Prednisone (VMP) With High Dose Melphalan Followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
A multicenter, open label, randomized phase ii study of mln9708 plus oral dexamethasone or plus oral cyclophosphamide and dexamethasone or plus bendamustine and dexamethasone or plus oral cyclophosphamide, thalidomide and dexamethasone followed by maintenance with mln9708 or placebo treatment in newly diagnosed elderly multiple myeloma patients
Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethason vs Pomalidomide maintenance for patients with Multiple Myeloma in first relapse after prior 1st line treatment with Lenalidomide and Bortezomib.
A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor: The APOLLO Study
A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-Dose Therapy
A multicenter, open label, randomized phase ii study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (dara-vcd) versus the association of bortezomib-thalidomide-dexamethasone (vtd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (mm) young patients eligible for autologous stem cell transplantation